BioCentury
ARTICLE | Financial News

Stealth, AOBiome propose Hong Kong offerings

July 3, 2018 10:10 PM UTC

Stealth BioTherapeutics Corp. (Newton, Mass.) and AOBiome Therapeutics Inc. (Cambridge, Mass.) each proposed on Tuesday to list on Hong Kong Exchanges and Clearing Ltd. (HKEX).

Stealth’s lead candidate is elamipretide, a mitochondrial-targeting tetrapeptide that binds and stabilizes cardiolipin to promote electron transfer and prevent apoptosis. The candidate is in a global Phase III trial to treat mitochondrial myopathy and a Phase II/III trial to treat Barth syndrome. Stealth plans to start a Phase IIb trial of the candidate to treat dry age-related macular degeneration (AMD) around year end and a Chinese Phase II/III trial to treat Leber’s hereditary optic neuropathy (LHON) in 1H19...